Data Updates in GI Cancers and HCC from ESMO 2024 - Episode 1
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, on 5-year data for tremelimumab plus durvalumab in unresectable HCC.
Related Content: